Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)

Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 30; pp. v624 - v625
Main Authors: Shah, R., Girard, N., Nagar, S.P., Griesinger, F., Roeper, J., Davis, K., Bakker, N., Thakrar, B., Taylor, A., Feliciano, J.
Format: Journal Article
Language:English
Published: 01-10-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1093/annonc/mdz260.044